Nanotechnology-based Systems Research Articles

Nanotechnological advancement for the treatment of neurodegenerative disorders

Neurodegenerative disorders are chronic and progressive conditions of the central nervous system. This review work focusses on some of the disorders like Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis, and Huntington’s disease which are some of the most prevalent neurodegenerative disorders presenting a substantial challenge on the global health care system. These disorders are characterized by the loss of neurons and the formation of protein aggregates leading to cognitive and motor impairments. The treatment options are available but due to the complex pathophysiology of the disease and the intricate structure of the brain, effective concentrations of drugs are not delivered to brain. Here we discuss some of the recent strategies employed by scientists to enhance the drug delivery and drug targeting to the site of action that is brain for these disorders. Further, nanotechnology-based carrier systems have been discussed which are developed using different natural and synthetic polymers and lipid materials. Owing to many beneficial properties like nanometric size range, physicochemical properties and tunable surface-modifying features, nanocarriers serve as potential systems in the treatment of neurodegenerative diseases as they can easily cross the BBB and reach to the brain in effective concentration. This review article describes neurodegenerative disorders and the limitations associated with their conventional application. Different arrays of nanocarriers such as polymeric nanoparticles, liposomes, Solid Lipid Nanoparticles, Nanostructured Lipid Carriers, and Nanoemulsions have been extensively reviewed. To understand the nanomedicine market, the ongoing clinical trials for various nano-carriers employed to treat these disorders have been compiled and discussed.

Chitosan nanoparticle encapsulation improves the effect of donepezil on impaired memory in an amnesia mouse model

ObjectiveAmnesia is one of the most important parts of Alzheimer’s disease (AD). Among the conventional and controlled drug delivery strategies for the pharmacological treatment of AD, nanotechnology-based systems targeting pharmacologically active molecules near their site of action seem to be the most effective. So, this study aimed to investigate the nano-chitosan encapsulated Donepezil on impaired memory in a mouse model of AD.MethodThis study was conducted on 232 male NMRI mice (30–35 mg) and carried out in three phases to identify the optimal ethanol dose for amnesia induction; to evaluate the effect of donepezil alone and donepezil enclosed in chitosan nano-particles after ethanol-induced amnesia. The effect of treatment was evaluated in an inhibitory passive avoidance apparatus. The data was recorded and analyzed in GraphPad Prism software using ANOVA and Tukey post hoc test. p < 0.05 was considered as the first significant level.ResultsIntraperituneally (IP) injection of 0.25, 0.5, 0.75, or 1 mg/kg non-capsulated or chitosan-encapsulated donepezil significantly improved impaired memory compared to that of the controls. However, at doses of 0.25 and 0.5 mg/kg, nano-chitosan-encapsulated donepezil had significantly greater effects than non-encapsulated donepezil (p < 0.0001 and p < 0.05, respectively).ConclusionEncapsulation could reduce the required dose to achieve the desired memory improvement effect. Further studies are required to understand the efficiency of nano-chitosan-encapsulated donepezil administered via different delivery routes and the underlying mechanism of its improved effect on impaired memory.

Innovative Nanocomposites for Drug Delivery: A Novel Approach for Diabetic Foot Ulcer.

Diabetic Foot Ulcer (DFU) is a chronic wound, and a person with diabetes has an increased lifetime risk of foot ulcers (19%-34%) and high morbidity (65% recurrence in 3-5 years, 20% lifetime amputation). Recent data have shown rising amputation rates, especially in the younger and minority populations. This abstract discusses innovative approaches for addressing this issue. This highlights the use of nanotechnology-based drug nanocomposite systems for natural wound healing therapies, with a focus on nanoparticles, nano-emulsions, and nanogels. This review also emphasizes the potential of hydrogels for drug delivery, highlighting their versatility in various medical applications. Furthermore, it delves into the use of silver nanoparticles (AgNP's) for treating diabetic wounds while acknowledging the need to address potential toxicity concerns. Finally, the abstract discusses the utilization of traditional herbal medicine and the integration of modern science to advance wound care, particularly focusing on wound microbiome, immune response, and controlled herbal medicine delivery. This study also highlights clinical trials conducted on DFU. Overall, these abstracts highlight the importance of exploring diverse and innovative solutions to chronic wound management.

A Review on Novel Applications of Nanotechnology in the Management of Prostate Cancer.

Prostate cancer continues to be a serious danger to men's health, despite advances in the field of cancer nanotechnology. Although different types of cancer have been studied using nanomaterials and theranostic systems derived from nanomaterials, they have not yet reached their full potential for prostate cancer due to issues with in vivo biologic compatibility, immune reaction responses, accurate targetability, as well as a therapeutic outcome related to the nano-structured mechanism. The ultimate motive of this article is to understand the theranostic nanotechnology-based scheme for treating prostate cancer. The categorization of diverse nanomaterials in accordance with biofunctionalization tactics and biomolecule sources has been emphasized in this review so that they might potentially be used in clinical contexts and future advances. These opportunities can enhance the direct visualization of prostate tumors, early identification of prostate cancer-associated biomarkers at extremely low detection limits, and finally, the therapy for prostate cancer. In December 2022, a thorough examination of the scientific literature was carried out utilizing the Web of Science, PubMed, and Medline databases. The goal was to analyze novel applications of nanotechnology in the treatment of prostate cancer, together with their structural layouts and functionalities. The various treatments and the reported revolutionary nanotechnology-based systems appear to be precise, safe, and generally successful; as a result, this might open up a new avenue for the detection and eradication of prostate cancer.

Nanotechnology-based approaches for targeted drug delivery for the treatment of respiratory tract infections

Background: Nanotechnology has emerged as a promising field for the diagnosis, monitoring, and treatment of respiratory tract infections (RTIs). By leveraging the unique properties of nanoscale delivery systems, nanotechnology can significantly enhance the selectivity and efficacy of antimicrobials, thereby reducing off-target effects. Objective: This review explores the development and application of targeted nanosystems in combating viral, bacterial, and fungal RTIs. Nanotechnology-based systems, including biological and non-biological nanoparticles, offer innovative solutions for overcoming antimicrobial resistance, improving drug bioavailability, and minimizing systemic side effects. RTIs are a leading cause of morbidity and mortality globally, particularly affecting vulnerable populations such as children, the elderly, and immunocompromised individuals. Traditional drug delivery methods face numerous challenges, such as rapid clearance, poor tissue penetration, and drug degradation. Nanoparticle-based delivery systems address these issues by enhancing tissue penetration, providing sustained drug release, and enabling targeted delivery to infection sites. These systems include liposomal delivery, polymeric nanoparticles, dendrimers, and metal-based nanoparticles, each offering unique advantages in treating RTIs. Nanotechnology also plays a crucial role in vaccine development by offering new strategies to enhance immune responses and improve antigen delivery. Furthermore, the review discusses the clinical translation and regulatory considerations for nanotechnology-based drug delivery, emphasizing the need for rigorous testing and quality control to ensure safety and efficacy. Conclusion: Nanotechnology offers promising advancements in the treatment, and prevention of RTIs by enhancing drug delivery and efficacy. By addressing challenges such as antimicrobial resistance and poor tissue penetration, nanotechnology-based systems have the potential to significantly improve patient outcomes.

Advancements in Nanotechnology-Based Paclitaxel Delivery Systems: Systematic Review on Overcoming Solubility, Toxicity, and Drug Resistance Challenges in Cancer Therapy

Background: Paclitaxel (PTX) is a potent chemotherapeutic widely used to treat cancers, including breast and ovarian cancer. However, its poor water solubility, severe side effects, and susceptibility to multidrug resistance (MDR) limit its clinical effectiveness. Recent research focuses on nanotechnology-based delivery systems, such as nanoparticles, liposomes, and dendrimers, to enhance PTX solubility, bioavailability, and targeted delivery. This systematic review analyzed studies from 2019 to 2023 that explore advancements in PTX delivery, focusing on improving therapeutic outcomes and reducing toxicity. Methods: A systematic search was conducted using PubMed, Scopus, Google Scholar, and Web of Science. Forty-five primary research studies meeting inclusion criteria for nanotechnology-based systems, targeted delivery, and MDR strategies were analyzed for improvements in PTX delivery efficacy. Results: The review identified significant advancements in PTX delivery through nanoparticle and targeted systems. Polymer-based nanoparticles, ligand-conjugated carriers, and co-delivery systems with MDR inhibitors showed improved PTX solubility, stability, and selective targeting. Theragnostic platforms combining diagnostics and therapy offered real-time tracking, enhancing personalized treatment. Conclusion: While nanotechnology-based PTX delivery shows promise in overcoming PTX's limitations, challenges remain, particularly in nanoparticle stability, tumor microenvironment barriers, and regulatory hurdles. Future research should address these challenges to enable the clinical translation of PTX systems, providing more effective, accessible cancer treatments worldwide.

Advanced Nanotechnological Approaches for Biofilm Prevention and Control

Biofilm-associated infections present a significant challenge in modern medicine, primarily due to their resilience and resistance to conventional treatments. These infections occur when bacteria form biofilms, protective layers formed by bacterial communities, which are notoriously resistant to traditional antibiotics on surfaces such as medical implants and biological surfaces, making eradication with standard antibiotics difficult. This resilience leads to persistent infections, imposing a substantial economic burden on healthcare systems. The urgency to find alternative treatments is critical as current methods are insufficient and costly. Innovative approaches, such as nanotechnology-based therapies, offer promising alternatives by targeting biofilms more effectively and reducing the need for invasive procedures. Nanocarriers hold significant promise in the fight against biofilm-associated infections. Nanocarriers can penetrate biofilms more effectively than conventional treatments, delivering higher concentrations of antibiotics or other antimicrobial agents precisely where they are needed. This targeted approach not only enhances the efficacy of treatments but also minimizes potential side effects. The development of nanocarrier-based therapies is crucial for overcoming the limitations of current treatments and ultimately improving patient outcomes and reducing the economic burden of biofilm-associated infections on healthcare systems. In this review, nanotechnology-based systems, their characteristics, limitations, and potential benefits are explored to address biofilms-related infections. Additionally, biofilm evaluation models and the tests necessary for the preclinical validation of these nanosystems to facilitate their clinical application are addressed.

Design of ternary reversible Feynman and Toffoli gates in ternary quantum-dot cellular automata

The use of reversible logic gates leads to a reduction in energy loss in logic circuits by preventing information loss. New computing methods, such as quantum-dot cellular automata (QCA), have been offered by nanotechnology emerging with nanoelectronics to make more comprehensive logic circuits. In nanotechnology-based systems, some bits are erased when the system performs any computation, and this causes heat dissipation and energy loss in systems. Adder circuits are the basis of any arithmetic operation and one of the main parts of many circuits for creating complex hardware; therefore, the use of enhanced adder circuits leads to high performance in logic circuits. In irreversible logic, the energy that is transferred from the power supply to the circuit is converted into heat, and energy loss occurs. Power management plays a vital role in modern computational systems, and using ternary logic instead of previous technologies leads to better performance. The main purpose of our study is to design ternary quantum-dot cellular automata (TQCA) reversible logic gates based on ternary quantum-dot cellular technology. Reversible gates are the basis of creating a reversible circuit. In this paper, the Muthukrishnan-Stroud (M-S) gate, which is the basis of all other reversible ternary gates, is implemented in ternary QCA technology, and then, reversible ternary Feynman and Toffoli (C2NOT) gates are designed. More optimal adder circuits can be realized in three-valued technology using Feynman and Toffoli gates. The area, delay, and cell count of the proposed TQCA designs are compared with those of other related works, and the effect of fault on the designs in the presence of cell omission defect is determined. The occupied areas of the proposed Feynman and Toffoli gate designs are 0.069 μm2 and 0.073 μm2, respectively. Moreover, the fault tolerance levels of these TQCA gates are 77% and 92%, respectively.

Advancing Ocular Medication Delivery with Nano-Engineered Solutions: A Comprehensive Review of Innovations, Obstacles, and Clinical Impact.

Recent advancements in ocular drug delivery have led to the introduction of a range of nanotechnology-based systems, such as polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, inorganic nanoparticles, niosomes, liposomes, nanosuspensions, dendrimers, nanoemulsions, and microemulsions. These systems enhance drug retention, penetration, bioavailability, and targeted delivery, promising prolonged drug release, and improved patient compliance. However, their interactions with biological systems pose potential toxicity risks, necessitating a careful evaluation of nanoparticle size, shape, surface charge, and coating. Traditional ocular drug delivery methods, like topical applications and injections, face challenges due to anatomical and physiological barriers, leading to frequent dosing and systemic toxicity risks. Nanocarriers offer solutions by improving drug permeation and targeted delivery, yet translating these innovations from research to clinical practice involves overcoming hurdles related to manufacturing scale-up, quality control, regulatory approval, and cost-effectiveness. The quality by design (QbD) framework provides a systematic approach to optimize nanocarrier formulation and process design, ensuring safety and efficacy. Assessing the safety of nanocarriers through in vivo and in vitro studies is crucial for their clinical application. This review explores the use of various nanomedicines in ocular drug delivery, highlighting the current state of ocular medication delivery and considering critical aspects such as scaling up and clinical applications.

Investigations of nanomaterial-based membranes for efficient removal of contaminants from wastewater via membrane distillation: a critical review

The requirement for wastewater treatment is paramount in ensuring environmental sustainability and safeguarding public health. As industrialization and urbanization accelerate, the volume of wastewater generated continues to increase, containing a diverse range of pollutants and contaminants. Untreated wastewater poses serious threats to ecosystems, water bodies, and human communities, leading to pollution, waterborne diseases, and ecological imbalances. Effective wastewater treatment becomes essential to mitigate these adverse effects by removing or reducing pollutants before discharge into natural water sources. This process helps to preserve water quality, protect aquatic life, and maintain the overall health of ecosystems. Membrane distillation (MD) has emerged as a promising technology for wastewater treatment, offering an innovative approach to address the challenges associated with conventional treatment methods. In MD, a hydrophobic membrane serves as a selective barrier, allowing water vapor to pass through while preventing the passage of contaminants. This paper offers an extensive overview of the latest advancements in nanotechnology and membrane distillation applied in wastewater treatment. We will delve into different types of nanomaterials that have been used to enhance the properties of MD membranes, such as nanocomposites, nanoparticles, and nanofiber membranes. We also explore the mechanisms by which these nanomaterials improve the separation efficiency, anti-fouling properties, and durability of MD membranes. Additionally, we highlight the potential of hybrid membranes that combine different types of nanomaterials for further improving the performance of MD in wastewater treatment. We provide examples of recent studies that have investigated the use of hybrid membranes, including carbon nanotube-graphene oxide hybrid membranes, nanocomposite nanofiber membranes, and silver nanoparticle-embedded membranes. We also identify some areas for future research and development, such as the scale-up and commercialization of nanotechnology-based MD systems. In summary, this review paper highlights the potential of nanotechnology to enhance the performance of MD in wastewater treatment, leading to improved water quality and a cleaner environment.

Biopolymer Drug Delivery Systems for Oromucosal Application: Recent Trends in Pharmaceutical R&D.

Oromucosal drug delivery, both local and transmucosal (buccal), is an effective alternative to traditional oral and parenteral dosage forms because it increases drug bioavailability and reduces systemic drug toxicity. The oral mucosa has a good blood supply, which ensures that drug molecules enter the systemic circulation directly, avoiding drug metabolism during the first passage through the liver. At the same time, the mucosa has a number of barriers, including mucus, epithelium, enzymes, and immunocompetent cells, that are designed to prevent the entry of foreign substances into the body, which also complicates the absorption of drugs. The development of oromucosal drug delivery systems based on mucoadhesive biopolymers and their derivatives (especially thiolated and catecholated derivatives) is a promising strategy for the pharmaceutical development of safe and effective dosage forms. Solid, semi-solid and liquid pharmaceutical formulations based on biopolymers have several advantageous properties, such as prolonged residence time on the mucosa due to high mucoadhesion, unidirectional and modified drug release capabilities, and enhanced drug permeability. Biopolymers are non-toxic, biocompatible, biodegradable and may possess intrinsic bioactivity. A rational approach to the design of oromucosal delivery systems requires an understanding of both the anatomy/physiology of the oral mucosa and the physicochemical and biopharmaceutical properties of the drug molecule/biopolymer, as presented in this review. This review summarizes the advances in the pharmaceutical development of mucoadhesive oromucosal dosage forms (e.g., patches, buccal tablets, and hydrogel systems), including nanotechnology-based biopolymer nanoparticle delivery systems (e.g., solid lipid particles, liposomes, biopolymer polyelectrolyte particles, hybrid nanoparticles, etc.).

Nanotechnology: A promising tool for targeted drug delivery

Nanotechnology has eventually and strongly engaged in the field of drug delivery. It makes use of the specific properties of the substance at the Nano scale. Their primary goal is to increase therapeutic effects while reducing adverse effects. Due to their improved goods, nanotechnology has become more popular across a variety of industries. The term “Nano medicine” is used to denote the application of nanotechnology in medicine. This Nano medicine is essential for drug delivery, antibacterial, vaccine development, wearable technology, diagnostic and imaging tools, implants, high throughput screening platforms, etc. It makes use of biological, biomimetic, no biological, or hybrid materials. To attain logical drug delivery, it is important to understand the interlink age between nanoparticles and the biological environment, drug release, and targeting cell-surface receptors. We can control disease progression by using nanomaterial including peptide-based nanotubes to prey the vascular endothelial growth factor (VEGF) receptor. Also, the use of herbal medicine has been used since ancient times. The supply of active compounds is shown by the effectiveness of various species of herbal medicine. The essential requirements for extending novel nanotechnology-based medication delivery systems are highlighted in this review.

DNA nanotechnology-based nucleic acid delivery systems for bioimaging and disease treatment.

Nucleic acids, including DNA and RNA, have been considered as powerful and functional biomaterials owing to their programmable structure, good biocompatibility, and ease of synthesis. However, traditional nucleic acid-based probes have always suffered from inherent limitations, including restricted cell internalization efficiency and structural instability. In recent years, DNA nanotechnology has shown great promise for the applications of bioimaging and drug delivery. The attractive superiorities of DNA nanostructures, such as precise geometries, spatial addressability, and improved biostability, have enabled them to be a novel category of nucleic acid delivery systems for biomedical applications. In this review, we introduce the development of DNA nanotechnology, and highlight recent advances of DNA nanostructure-based delivery systems for cellular imaging and therapeutic applications. Finally, we propose the challenges as well as opportunities for the future development of DNA nanotechnology in biomedical research.

Design of nanoparticle-based systems for the systemic delivery of chemotherapeutics: Alternative potential routes via sublingual and buccal administration for systemic drug delivery.

Conventional therapeutic approaches for cancer generally involve chemo- and radiation therapies that often exhibit low efficacy and induce toxic side effects. Recent years have seen significant advancements in the use of protein biologics as a promising alternative treatment option. Nanotechnology-based systems have shown great potential in providing more specific and targeted cancer treatments, thus improving upon many of the limitations associated with current treatments. The unique properties of biomaterial carriers at the nanoscale have been proven to enhance both the performance of the incorporated therapeutic agent and tumor targeting; however, many of these systems are delivered intravenously, which can cause hazardous side effects. Buccal and sublingual delivery systems offer an alternative route for more efficient delivery of nanotechnologies and drug absorption into systemic circulation. This review concentrates on emerging buccal and sublingual nanoparticle delivery systems for chemo- and protein therapeutics, their development, efficacy, and potential areas of improvement in the field. Several factors contribute to the development of effective buccal or sublingual nanoparticle delivery systems, including targeting efficiency of the nanoparticulate carriers, drug release, and carrier biocompatibility. Furthermore, the potential utilization of buccal and sublingual multilayer films combined with nanoparticle chemotherapeutic systems is outlined as a future avenue for in vitro and in vivo research.

Synergistic effects of multidrug/material combination deliver system for anti-mutidrug-resistant tumor

Multidrug resistance (MDR) is a public health issue of particular concern, for which nanotechnology-based multidrug delivery systems are considered among the most effective suppressive strategies for such resistance in tumors. However, for such strategies to be viable, the notable shortcomings of reduced loading efficiency and uncontrollable drug release ratio need to be addressed. To this end, we developed a novel “multidrug/material” co-delivery system, using d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS, P-gp efflux pump inhibitor) and poly(amidoamine) (PAMAM) to fabricate a precursor material with the properties of reversing MDR and having a long-cycle. Further, to facilitate multidrug co-delivery, we loaded doxorubicin(Dox) and curcumin(Cur, cardiotoxicity modifier and P-gp inhibitor) into PAMAM-TPGS nano-micelles respectively, and mixed in appropriate proportions. The multidrug/material co-delivery system thus obtained was characterized by high drug loading and a controllable drug release ratio in the physiological environment. More importantly, in vitro and in vivo pharmacodynamic studies indicated that the multidrug/material co-delivery system facilitated the reversal of MDR. Moreover, the system has increased anti-tumor activity and is biologically safe. We accordingly propose that the “multidrug/material” co-delivery system developed in this study could serve as a potential platform for reversing MDR and achieving safe and effective clinical treatment.

Recent Advances in Nanocarrier Based Therapeutic and Diagnostic Approaches in Tuberculosis

&lt;img src=” https://s3.amazonaws.com/production.scholastica/article/90699/large/prnano_1072023gaf.jpg?1701882189”&gt; Tuberculosis is the second most fatal infectious disease; each year, it causes millions of deaths worldwide. Although several anti-TB drugs are currently available, the problem with these drugs is that they require a prolonged duration of treatment, with high drug doses. In addition, patient non-adherence to therapy subsequently leads to the development of multidrug-resistant and ex-tensively drug-resistant tuberculosis. Therefore, we need to develop an effective and robust nano-carrier-based drug delivery system to overcome these issues and improve the therapeutic potential of drug dose/duration and patient compliance. This review article focuses on the cur-rently available various nanotechnology-based therapeutic approaches, including lipid nanopar-ticles, polymeric particles, carbon nanotubes, glucan, and alginate-based nano-carrier systems for effective anti-TB drug delivery to host macrophage for mycobacterium killing. Finally, we also present some promising recent nanotechnology-based mycobacterial detection systems us-ing silver nanoparticles, silica nanoparticles, magnetic nanoparticles, quantum dots, and magnet-ic barcode assay that have recently emerged as the latest diagnostic tool. Functionalized nano-materials for emerging Aggregation-induced photodynamic therapy as next-generation theranostics have also been discussed as a novel option for TB diagnosis and therapy.

Thermo-responsive liposome nano-vesicles for co-delivery of emamectin benzoate and nitenpyram with synergistic pest control

The conventional pesticide formulations often suffer from low utilization rates and trigger the development of resistance, leading to significant resource waste and ecological damage. A promising solution to these issues lies in the design of intelligent, nanotechnology-based systems for controlled-release and co-delivery of pesticides. A multi-compartment liposome nano-vesicle (Co-EM-Lip) that simultaneously carries emamectin benzoate (EB) and nitenpyram (Nit) has been developed, using a eutectic mixture (EM) of fatty acids as a temperature-sensitive “switch”. This Co-EM-Lip system successfully enabled the co-delivery of two pesticides with differing water solubility and insecticidal pathways, along with a thermo-responsive controlled release. The effectiveness of Co-EM-Lip against Plutella xylostella was approximately 4.4 times higher at 35 °C than at 15 °C, which is attributable to high temperature-triggered rapid release properties. Importantly, EB and Nit within Co-EM-Lip demonstrated synergistic biological effects against various pests. Additionally, Co-EM-Lip showed less toxicity to zebrafish. This research thus introduces a novel strategy to devise smart, controlled-release and co-delivery pesticide systems aimed at enhancing pesticide efficiency, delaying pest resistance, and minimizing environmental harm and impact on non-target organisms.

Applications of Nanomedicine in Brain Tumor Therapy: Nanocarrierbased Drug Delivery Platforms, CChallenges, and Perspectives.

The most difficult kind of cancer to treat is brain cancer, which causes around 3% of all cancer-related deaths. The targeted delivery is improved with the use of technologies based on nanotechnology that are both safe and efficient. Because of this, there is now a lot of research being done on brain cancer treatments based on nanoformulations. In this review, the author's primary aim is to elucidate the various nanomedicine for brain cancer therapy. The authors focus primarily on the advancement of nanotechnology in treating brain cancer (BC). This review article gives readers an up-to-date look at publications on sophisticated nanosystems in treating BC, including quantum dots (QDs), nanoparticles (NPs), polymeric micelles (PMs), dendrimers, and solid lipid nanoparticles (SLNs), among others. This article offers insight into the use of various nanotechnology-based systems for therapy as well as their potential in the future. This article also emphasizes the drawbacks of nanotechnology-based methods. Future perspectives for treating brain cancer using proteomics and biomimetic nanosystems are briefly discussed. In this review, we review several aspects of brain cancer therapy, including various nanomedicines, their challenges and future perspectives. Overall, this article gives a thorough overview of both the present state of brain cancer treatment options and the disease itself.

Recent advances in nanocarrier-based drug delivery systems in treatment of rheumatoid arthritis

Rheumatoid arthritis(RA) is a widely prevalent autoimmune inflammatory disease that severely affects patients' quality of life. Currently, conventional formulations against RA have several limitations, such as nonspecificity, poor efficacy, large drug dosages, frequent administration, and systemic side effects. Nanotechnology-based drug delivery systems have emerged as a promising stra-tegy for the diagnosis and treatment of RA since nanotechnology can overcome the limitations of traditional treatments and simplify the complexity of the disease. These systems enable targeted delivery of anti-inflammatory drugs to the inflamed areas through active and passive targeting, achieving specificity to the joints, overcoming the need for increased dosage and administration frequency, and reducing associated adverse reactions. This article aimed to review nanocarrier-based drug delivery systems in the field of RA and elucidate how nanosystems can be utilized to deliver therapeutic drugs to inflamed joints for controlling RA progression. By discussing the current issues and challenges faced by nanodrug delivery systems and highlighting the urgent need for solutions, this article offers theoretical support for further research on nanotechnology-based co-delivery systems in the future.

Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.

Glioblastoma multiforme (GBM) is the deadliest brain tumor with a poor prognosis and limited therapeutic options. Temozolomide (TMZ) is the first-line chemotherapeutic agent used for the treatment of GBM; however, it suffers from several limitations, including short half-life, rapid metabolism, <1% brain bioavailability, methyl guanine methyl transferase (MGMT) based chemoresistance, and hematological toxicities. Several approaches have been adopted to overcome these limitations, particularly by using nanotechnology-based systems, but its physicochemical properties make TMZ challenging to load into these nanocarriers. In the current research, we conjugated TMZ with different fatty acids, i.e., linoleic acid (LA), oleic acid (OA), and palmitic acid (PA), to obtain TMZ-fatty acid conjugates, which are comparatively hydrophobic, less prone to degradation and potent. These conjugates were thoroughly characterized using 1H NMR spectroscopy, high-resolution mass spectrometry (HR-MS), and reverse phase-high performance liquid chromatography (RP-HPLC). The synthesized conjugates, namely Temozolomide-oleic acid (TOA,6R1), Temozolomide-linoleic acid (TLA, 6R2), and Temozolomide-palmitic acid (TPA, 6R3), showed an IC50 of 101.4, 67.97, and 672.04μM, respectively in C6 cells and 428.257, 366.43 and 413.69μM, respectively in U87-MG cells. On the other hand, the free TMZ showed an IC50 of >1000μM and 564.23μM in C6 and U87-MG, respectively. Further, the in vivo efficacy of the TMZ-fatty acid conjugates was evaluated in the C6-induced orthotropic rat glioblastoma model, wherein the TMZ-fatty acid conjugate showed improved survival rate (1.6 folds) and overall health of the animals. Collectively, the conjugation of fatty acids with TMZ improves its anticancer potential against glioblastoma multiforme (GBM).